Browsing Tag
diabetic retinopathy
8 posts
Kodiak Sciences (NASDAQ: KOD) bets Phase 3 momentum and 2027 cash runway can turn pipeline promise into a retina franchise
Kodiak Sciences is chasing a retina comeback with Phase 3 Zenkuda data, a longer cash runway, and major catalysts ahead. Read what happens next.
Palatin Technologies to raise $15.8m in public offering; NYSE relisting expected Nov 12
Palatin Technologies regains NYSE American compliance and secures $15.8M for its oral MC4R obesity drug. Find out how the relisting and IND impact its biotech trajectory.
Diabetic retinopathy: How diabetes can lead to vision loss and what you can do about it
Diabetic retinopathy is a serious and potentially blinding complication of diabetes that affects the retina—the part of the…
Kodiak Sciences advances Phase 3 study of tarcocimab tedromer in diabetic retinopathy
Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company focused on developing transformative therapeutics for retinal diseases, announced that…
EyePoint Pharmaceuticals reports mixed results for DURAVYU in Phase 2 diabetic retinopathy trial
EyePoint Pharmaceuticals, Inc., committed to innovative therapeutics for serious retinal diseases, today disclosed the top-line results of the…
ABBV-RGX-314 : REGENXBIO reports positive Phase 2 data on diabetic retinopathy gene therapy candidate
REGENXBIO Inc. has disclosed new findings from its Phase II ALTITUDE trial, focusing on ABBV-RGX-314 as a gene…
OcuTerra Therapeutics moves forward with OTT166 eye drops in Phase 2 trial
OcuTerra Therapeutics, a clinical-stage ophthalmology company, announced the successful full enrollment in its Phase 2 DR:EAM (Diabetic Retinopathy:…
FDA approves Genentech’s lucentis for comprehensive diabetic retinopathy treatment
Genentech, a member of the Roche Group, has received approval from the U.S. Food and Drug Administration (FDA)…